GSDMD and triple-A syndrome: Thus, DMFO could be a potential drug for AAA treatment with few side effects (Table 1).24 GSDMD is activated in macrophages and vascular smooth muscle cells in human plaques, which exacerbates atherogenesis; thus, inhibition of GSDMD and pyroptosis in atherosclerosis can be a potential therapeutic target.72